Impact of Targeted Therapy on Cancer-Related Cognitive Impairment (TKI)

June 5, 2026 updated by: Michelle Janelsins, PhD, MPH, University of Rochester NCORP Research Base
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.

Study Overview

Status

Recruiting

Conditions

Detailed Description

PRIMARY OBJECTIVE:

I. Characterize differences in subjective CRCI longitudinally among patients receiving TKIs for CML or CLL.

OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.

GROUP I: TKI recipients complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.

GROUP II: Cancer-free individuals complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.

Study Type

Observational

Enrollment (Estimated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • New York
      • Rochester, New York, United States, 14642
        • Recruiting
        • University of Rochester NCORP Research Base
        • Contact:
        • Principal Investigator:
          • Karen Mustian, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with a diagnosis of CML or CLL scheduled to receive first dose of TKI therapy within 30 days or have received first dose of TKI within the previous 30 days, as well as cancer-free individuals.

Description

Inclusion Criteria:

  • TKI RECIPIENTS: Participants must have a diagnosis of CML or CLL
  • TKI RECIPIENTS: Participants must be scheduled to receive their first dose of TKI therapy for CML or CLL within 30 days or have received their first dose of TKI therapy for CML or CLL within the previous 30 days
  • TKI RECIPIENTS: Participants must be ≥ 18 years of age
  • TKI RECIPIENTS: Participants must be able to speak and read English
  • TKI RECIPIENTS: Participants must be able to understand and willing to sign an informed consent document
  • CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be ≥ 18 years of age
  • CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to speak and read English
  • CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Participants must be able to understand and willing to sign an informed consent document
  • CANCER-FREE INDIVIDUALS SERVING AS CONTROLS: Each participant must be matched to a TKI recipient participant based on sex and age ±5 years (i.e., must be no more than 5 years older or younger than the TKI recipient participant)

Exclusion Criteria:

  • Participants must have no history of metastatic cancer, primary brain tumor, or brain irradiation
  • Participants must have no history of TKI therapy
  • Participants must have no history of cytotoxic chemotherapy, immune checkpoint inhibitor therapy, hormonal therapy, biologic therapy, radiotherapy within the past 5 years. However, permitted treatments include prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
  • Participants must have no history of stroke within the past year and no remaining cognitive symptoms from any stroke prior to the past year
  • Participants must have no history of head trauma with loss of consciousness within the year prior to consent
  • Participants must have no diagnosis of dementia or severe neurodegenerative disease impairing daily functioning
  • Participants must have no psychiatric condition that led to hospitalization within the past year
  • Participants must not be currently pregnant
  • Participants must not be colorblind based on self-report
  • Participants must not be study staff who have previously viewed or administered the objective cognitive function measures (e.g., CANTAB)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Observational group I
TKI recipients complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.
Observational group II
Cancer-free individuals complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective cognitive performance
Time Frame: 12 months
Will be assessed using the FACT-Cog. Will apply multilevel models to study data. Will include main effects of time, group, and the group X time interaction.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Rochester NCORP Research Base

Collaborators

National Cancer Institute (NCI)

Investigators

  • Study Chair: Michelle Janelsins, PhD, University of Rochester NCORP Research Base

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 21, 2025

Primary Completion (Estimated)

February 28, 2029

Study Completion (Estimated)

February 28, 2029

Study Registration Dates

First Submitted

April 22, 2026

First Submitted That Met QC Criteria

June 5, 2026

First Posted (Actual)

June 10, 2026

Study Record Updates

Last Update Posted (Actual)

June 10, 2026

Last Update Submitted That Met QC Criteria

June 5, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • URCC-24060 (Other Identifier: CTEP)
  • UG1CA189961 (U.S. NIH Grant/Contract)
  • R01CA287666 (U.S. NIH Grant/Contract)
  • NCI-2025-04174 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Lymphocytic Leukemia (CLL)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe